N[eed for treatment]{.smallcaps}, defined as the number of people who meet diagnostic criteria for substance use disorder, where that disorder is known to respond to effective interventions, is commonly estimated from surveys of self-reported symptoms (which lead to diagnoses), which then define the size of the potential population in need of treatment. Researchers have used such needs-based epidemiological models to plan for services (for example, [@B28], [@B27]; [@B33]; [@B39]; [@B41]). There are, however, substantial problems for needs-based estimates of treatment, as defined by formal diagnosis (e.g., [@B25]; [@B42]). The assumption behind the definition and measurement of unmet need for alcohol and other drug (AOD) treatment is that substance use diagnosis is an accurate reflection of those who need treatment in the population. This may be the case for medical diseases and mental health disorders ([@B40]) but may be less applicable for AOD. "Many experts have argued that diagnosis alone is not a good proxy for treatment need" ([@B40], p. 1941). It is not clear that all people who meet diagnostic criteria would need treatment. At the same time, there may be people who do not meet the formal diagnostic criteria (so-called subthreshold cases) who may be appropriate for treatment ([@B16]).

In addition, the very definition of the diagnostic criteria is arbitrary (see, for example, the research on the differences between DSM-IV and DSM-5, [@B31], [@B32]). Formal treatment services are not necessarily always required for remission of AOD problems; the role of maturation and spontaneous remission are important to acknowledge ([@B49]). Indeed, [@B40] have shown that people with a substance use disorder (and hence counted as "in need") who have not received treatment are more likely to remit than those with a substance use disorder who received treatment. Although this is likely attributable to baseline severity differences between the groups, it still demonstrates how the measurement of unmet need based on diagnosis may substantially overestimate the need for treatment.

Demand for treatment, defined as the number of people who are seeking treatment, is likely to be a more useful concept for treatment planning and reflects the reality of patient demand for services. Demand for treatment can be measured as the actual number of people who have sought treatment ([@B19], [@B20]; [@B21]; [@B22]). However, this assumes that past demand predicts future demand and that past demand reflects client needs; both of these assumptions are problematic.

An alternate method is to survey people about their intention to seek treatment. However, in population surveys, the majority of respondents report that they do not need treatment. For example, the U.S. National Survey on Drug Use and Health, 2010 data ([@B45]) showed that, of the 6,384 people who demonstrated a need for treatment (as defined by meeting diagnostic criteria and not being in receipt of treatment in the last 12 months), only 392 felt the need for treatment (6%) and 193 "made the effort to seek treatment" (unsuccessfully) (3%). In the U.S. National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), only 8.5% of those respondents with a substance use disorder perceived the need for treatment ([@B33]). Thus it is likely that perceived need for treatment may represent an underestimate of unmet demand.

Some researchers have generated composite measures of treatment demand. For example, [@B44] included diagnosis (DSM-IV) by severity, as well as relapse potential (e.g., the number of previous treatments) plus environmental risk (marital status, employment status, living arrangements, and so on). This measure accommodated factors consistent with the notion of demand for treatment, such as the individual's circumstances. In addition, they included preference-based need, obtained from a survey (what clients said they wanted).

An important consideration in estimating demand is the extent of the severity of the problem. For those with less severe alcohol or other drug disorders, the demand for treatment is likely to be lower. This requires that the demand estimation be built with considerations of problem severity in mind. The work led by Rush and colleagues ([@B35], [@B36]; [@B37], [@B38]) explicitly attends to the relationship between problem severity (acuity, complexity, and chronicity) and the continuum of care (from generic brief interventions to intensive specialist services). This recognizes that a single national or local estimate of unmet demand for treatment is not helpful for planners. Planners need to know the unmet demand for different service types by the different levels of client severity. One of the challenges for models such as these, then, is how to estimate the likelihood of treatment seeking by different subpopulations of severity (given that those with a less severe substance use disorder are also less likely to seek treatment). Rush and colleagues (2019) made extensive use of expert opinion (Delphi procedures) to derive the probable rates of help seeking for each subpopulation.

The aim of the research described in this article was to establish estimates of demand for AOD treatment in Australia by drug type, incorporating problem severity, and a spectrum of treatment rates. Furthermore, we sought to match the overall demand estimate with the number of people who have sought treatment---creating an unmet demand estimate. The simple quantum of demand is limited in its usefulness unless it is matched with an accurate estimate of currently met demand. This analysis provides essential information for health planners in developing a treatment service system that can accommodate the number of individuals who would be suitable for, would be likely to seek, and would benefit from AOD treatment in any one year. In addition, this article outlines an approach that could be undertaken by health planners in any country, highlighting the importance of both severity distribution and determining appropriate treatment rates.

Method
======

The Drug and Alcohol Service Planning (DASP) model, developed between 2010 and 2013 by the New South Wales (NSW) Ministry of Health (Mental Health and Drug and Alcohol Office), aimed to facilitate planning for AOD services in Australia and to provide a basis for national consistency in approaches to planning across all the Australian health jurisdictions. The model followed the principles of population-based planning used in the Mental Health Clinical Care and Prevention (MH-CCP) model of 2000 ([@B7]; [@B34]). The DASP model applied the prevalence of substance use disorders, by drug type and age group from epidemiological sources; incorporated a severity rating to distinguish mild, moderate, and severe presentations; and then used expert consensus (the Expert Reference Group) to estimate the treatment rate. The treatment rate reflected the proportion of all those who met diagnostic criteria who would be suitable for, likely to seek, and benefit from treatment in any one year (that is, demand for treatment). The severity ratings (assignment to mild, moderate, or severe disability) were important because these then drove differential treatment rates, and hence they are sensitive measures in terms of the model's prediction of the demand for treatment.

DASP predictions of treatment demand, therefore, relied on three key variables: the epidemiology (that is, the prevalence of AOD disorders in the community), the severity distribution (the distribution of people with AOD disorders into three disability categories: mild, moderate, and severe), and the treatment rates (the proportion of all people who would be suitable for, likely to seek, and benefit from treatment, given the appropriateness of the treatment services available).

Epidemiology
------------

The epidemiology for the model was based on the Australian Burden of Disease (AUSBoD) ([@B5]), which in turn relied largely on the 1997 National Survey of Mental Health and Wellbeing (NSMHWB; [@B3]; [@B24]). The Composite International Diagnostic Interview (CIDI) was used as the interview tool to establish the rates of ICD-10 diagnoses of dependence and harmful use of alcohol, cannabis, sedatives, opioids, and stimulants. The last two classes (opioids and stimulants) are very low-prevalence disorders in the general population, and general population surveys underestimate the prevalence of these drug classes ([@B12]; [@B24]). The DASP model therefore sought alternate epidemiology for heroin and stimulants (amphetamine).

The prevalence rates, their sources, along with the actual population numbers (using the 2006 Australian population estimates taken from the Australian Bureau of Statistics \[ABS\] online publication *3222.0 -- Population Projections, Australia, 2006 to 2101, Series B*) are given in [Table 1](#T1){ref-type="table"}. This assumes that the prevalence rates from the 1997 survey still applied in 2006.

###### 

Past-12-month prevalence rates applied in the DASP model, associated data source and population, by drug type

![](jsads.2019.s18.42tbl1)

                   SUD pop.                                                       
  ---------------- ---------- ------- -------- --------- -------- --------------- ------------------------------------------------------------------------------------------------------------
  Alcohol          6.35%      1.42%   18,300   916,925   48,090   983,315         AUSBoD data from NSMHWB (see the AUSBoD report [@B5], pp. Annex [Table 2](#T2){ref-type="table"}, p. 210).
  Amphetamine      0.51%      0.01%   2,190    73,729    271      76,190          As reported in AUSBoD--- used NMDS-AODT and a ([@B30]) multiplier
  Benzodiazepine   0.38%      0.08%   224      54,251    2,570    57,045          AUSBoD data from NSMHWB
  Cannabis         1.76%      0.05%   8,348    254,661   1,725    264,734         AUSBoD data from NSMHWB
  Opioids          0.65%      0.11%   535      94,506    3,619    98,660          ([@B9])
  **Total**                                                       **1,479,944**   

*Notes:* DASP = Drug and Alcohol Service Planning; SUD = substance use disorder; pop. = population; AUSBoD = Australian Burden of Disease; NSMHWB = National Survey of Mental Health and Wellbeing.

Per 100,000 age-specific population.

Severity distribution and treatment rate
----------------------------------------

The DASP model distinguished between mild, moderate, and severe disability. The division into mild, moderate, and severe disability was facilitated by the available Australian data on disability weights from AUSBoD ([@B5]), which in turn relied on the 12-Item Short Form Survey (SF12) measure of functioning. The proportion of those meeting diagnostic criteria who would fall within the severe disability category, using the AUSBoD disability weights, was calculated first and then was combined with existing research and expert judgment to divide the remaining numbers between mild and moderate disability.

The ratio of mild to moderate to severe disability for alcohol was 6:2:1; that is, for every 6 people mildly disabled, there were 2 moderately disabled and 1 severely disabled ([Table 2](#T2){ref-type="table"}). The same ratio was used for cannabis (6:2:1). For opioids, no one was classed as having a mild or moderate disability (all were placed in the severe category). For amphetamines, no one was classed as having a mild disability, and, for every 9 severely disabled, there was one moderately disabled. Last, for benzodiazepines, for every 5 people classed as mildly disabled, 3 were classed as moderately disabled and 2 as severely disabled (5:3:2).

###### 

DASP model treatment rates for drug class by severity distributions
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  Drug type        Severity distribution   Treatment rate
  ---------------- ----------------------- ------------------------------------------
  Alcohol                                  
   Mild            67%                     20%
   Moderate        22%                     50%
   Severe          11%                     100%
  Amphetamine                              
   Mild            0%                      0%
   Moderate        10%                     50%
   Severe          90%                     35%[*^a^*](#tblfn4){ref-type="table-fn"}
  Benzodiazepine                           
   Mild            50%                     20%
   Moderate        30%                     50%
   Severe          20%                     100%
  Cannabis                                 
   Mild            67%                     20%
   Moderate        22%                     50%
   Severe          11%                     100%
  Opioids                                  
   Mild            0%                      0%
   Moderate        0%                      0%
   Severe          100%                    90%

*Notes:* DASP = Drug and Alcohol Service Planning.

The treatment rate for amphetamine was subject to substantial debate among the expert group, and, although retained at 35% for severe, this number is able to be modified by DASP model end users should they wish.

The treatment rates for each category of severity were established for the DASP model based on existing research and the judgment of the Expert Reference Group. In the 1997 NSMHWB survey ([@B4]), 14% of those with substance use disorders had used services in the past year. A decade later, in the 2007 Australian NSMHWB survey ([@B43]), 24% of the respondents with substance use disorders used treatment services in the past 12 months. The 2007 figure then informed the absolute minimum treatment rate for the DASP model. In theory the maximum treatment rate would be 100%---that is, everyone with mild, moderate, and severe disability who meets diagnostic criteria for substance use disorder would receive treatment. This is unrealistic for several reasons: (a) spontaneous remission, or natural recovery, is not uncommon (a proportion will never require treatment); (b) some people will seek support for behavior change through unfunded or informal means (such as mutual aid/self-help); (c) some people will not find the AOD services an appropriate match for their needs; and (d) some people will not see the need for treatment and not seek care.

Therefore, the DASP model required expert judgments about treatment rates that incorporated these factors. These expert judgments were informed by earlier research that noted an ideal treatment coverage of 51% for alcohol use disorders (70% for harmful use and 30% for dependence; see also [@B1]). Subsequently, the same team reduced this to an average of 38% (50% alcohol harmful use and 25% alcohol dependence) ([@B2]). In light of the minimum rate of 24% and a possible optimal rate of 51% as an overall treatment rate (across the severity distribution), the experts deliberated over a series of meetings (having been provided with the above data along with current treatment rates) until consensus was reached among the group. The resultant treatment rates are given in [Table 2](#T2){ref-type="table"}. Thus, for example, for those with AUD at mild severity (which represents 67% of all AUD), there is a presumed treatment rate of 20%, whereas for those with a severe AUD (11% of all AUD), the treatment rate is 100%. When averaged across severity types, the treatment rate for alcohol was 35%, for amphetamines 36%, for benzodiazepines 45%, for cannabis 35%, and for opioids 90%. It should be noted that there was substantial and sustained debate about the treatment rates in the DASP Expert Reference Group. In addition, end users can modify the treatment rates if they wish.

Sensitivity analyses
--------------------

Given the significant uncertainties associated with the prevalence rates, the severity distribution, and the treatment rates, a series of sensitivity analyses was undertaken to show how the demand estimates varied with changes in prevalence, severity, and treatment rate. We varied only one of the three parameters at a time, and when we varied a parameter we varied it across all age groups. The prevalence rates were altered by 25 percentage points (both higher and lower), per drug class, per age group. The analyses revealed a linear relationship between the changed prevalence and the predicted demand (and for this reason they are not reported further herein).

For the severity distribution, there was no pre-existing research or guidance to inform the decisions about the percentage changes to be applied, and each drug class needed to be considered separately. The severity distributions for alcohol, benzodiazepines, and cannabis were varied by 10 percentage points. For amphetamine, the minimum severity was varied by 20 percentage points (given 0% in mild severity), and for opioids it was a 30 percentage point change (and no alteration to the maximum as this was the base case). (See [Table 3](#T3){ref-type="table"}. Note that the severity distributions need to sum to 100%.)

###### 

Sensitivity analyses: summary of variations to be tested

![](jsads.2019.s18.42tbl3)

  Drug type        DASP model original severity distribution   SA 1 minimum severity distribution   SA 2 maximum severity distribution   DASP model original treatment rate   SA 3 minimum treatment rate   SA 4 maximum treatment rate
  ---------------- ------------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------ ----------------------------- -----------------------------
  Alcohol                                                                                                                                                                                                   
   Mild            67%                                         77%                                  67%                                  20%                                  20%                           30%
   Moderate        22%                                         12%                                  12%                                  50%                                  30%                           60%
   Severe          11%                                         11%                                  21%                                  100%                                 90%                           100%
  Amphetamine                                                                                                                                                                                               
   Mild            0%                                          0%                                   0%                                   0%                                   0%                            0%
   Moderate        10%                                         30%                                  0%                                   50%                                  40%                           70%
   Severe          90%                                         70%                                  100%                                 35%                                  25%                           55%
  Benzodiazepine                                                                                                                                                                                            
   Mild            50%                                         60%                                  50%                                  20%                                  10%                           50%
   Moderate        30%                                         20%                                  20%                                  50%                                  40%                           50%
   Severe          20%                                         20%                                  30%                                  100%                                 90%                           100%
  Cannabis                                                                                                                                                                                                  
   Mild            67%                                         67%                                  67%                                  20%                                  10%                           50%
   Moderate        22%                                         32%                                  12%                                  50%                                  40%                           50%
   Severe          11%                                         1%                                   21%                                  100%                                 100%                          90%
  Opioids                                                                                                                                                                                                   
   Mild            0%                                          0%                                   0%                                   0%                                                                 
   Moderate        0%                                          30%                                  0%                                   0%                                                                 
   Severe          100%                                        70%                                  100%                                 80%                                                                

*Notes:* DASP = Drug and Alcohol Service Planning; SA = sensitivity analysis.

Again, no past research could inform the sensitivity analyses on the treatment rate. A three-step method was used for the treatment rates: first, systematic application of new rates for mild, then moderate and severe treatment rates; followed by selection of those analyses providing minimum and maximum changes; then third, selection of those rates that had face validity (i.e., were clinically realistic). More specifically, the treatment rates were initially systematically varied by increasing mild treatment to 50% and keeping moderate and severe treatment constant; decreasing mild treatment to 10%, decreasing moderate treatment to 10%, and keeping severe treatment at 100%; keeping mild and moderate treatment rates the same as the base case (20% and 50%, respectively) and decreasing the severe treatment rate to 90%; and finally keeping the mild treatment rate at 20%, decreasing the moderate treatment rate to 30%, and decreasing the severe treatment rate to 90%. We examined the results of these analyses and determined those that produced the minimum and maximum change in predicted numbers being treated. This was then moderated by the knowledge of the current Australian treatment service system and treatment-seeking rates to ensure that the sensitivity analyses were clinically realistic. For example, a mild treatment rate of 50% for alcohol use disorders would not be feasible in practice. The resulting treatment rates used in the sensitivity analyses reported here are given in [Table 3](#T3){ref-type="table"}.

Polydrug use adjustment
-----------------------

The DASP model treated each drug class independently, thus potentially double counting individuals who may have both an alcohol use and a cannabis use disorder, for example. The most parsimonious way to deal with this problem is to adjust the prevalence rates---that is, to reduce the prevalence numbers by those who are dually (or triply) diagnosed. Using Australian data on dual diagnoses ([@B13]; [@B47], [@B48]), adjustments for the overlap between alcohol and cannabis were possible, but no specific data were available to adjust for the other specific drug classes (they were treated as "other drug" together).

Results
=======

Estimating treatment demand
---------------------------

In the first instance, we report estimates without any adjustment for polydrug use. [Table 4](#T4){ref-type="table"} provides the predicted demand for treatment for the main estimate and the four sensitivity analyses.

###### 

Predicted/modeled demand (number of people receiving treatment in the course of 1 year) main estimate and sensitivity analyses
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  Drug type        Main estimate − demand   SA 1: Minimum severity distribution[*^a^*](#tblfn7){ref-type="table-fn"}   SA 2: Maximum severity[*^a^*](#tblfn7){ref-type="table-fn"}   SA 3: Minimum treatment rate[*^b^*](#tblfn8){ref-type="table-fn"}   SA 4: Maximum treatment rate[*^b^*](#tblfn8){ref-type="table-fn"}
  ---------------- ------------------------ -------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------
  Alcohol          348,094                  318,594                                                                    397,260                                                       294,012                                                             435,609
  Amphetamine      27,810                   26,667                                                                     30,095                                                        20,190                                                              43,047
  Benzodiazepine   25,671                   23,959                                                                     28,523                                                        19,966                                                              34,227
  Cannabis         93,716                   80,479                                                                     106,953                                                       70,154                                                              144,015
  Opioids          98,660                   69,062                                                                     98,659                                                        78,928                                                              98,659
  All drugs        593,951                  518,761                                                                    661,490                                                       483,250                                                             755,557

*Notes:* SA = sensitivity analysis.

Assuming prevalence and treatment rate remain constant;

assuming prevalence and severity distribution remain constant.

The main estimate predicted that the treatment demand would be for 593,951 people in Australia over 1 year ([Table 4](#T4){ref-type="table"}). As can be seen, the majority are for alcohol treatment (348,094: 58.6%). The sensitivity analyses revealed that the demand may be as low as 483,250 or as high as 755,557, depending on the choices about both severity distribution and treatment rate. The size of the difference in the ranges (in the order of 272,000 people) shows the importance of choosing the severity distribution and treatment rate parameters carefully. There is no objective evidence base to support one preferred distribution of severity and treatment rate over another. It relies on making expert judgments.

As expected, the adjustments for polydrug presentations resulted in lower overall estimate of demand (503,340)with a high estimate of 621,355 (based on SA 4), and a low estimate of 411,740 (SA 1; [Table 5](#T5){ref-type="table"}). Relative to the main demand estimate (593,951), the lowest estimate of 411,740 was predicated on modeling a lower treatment rate and accommodating a polydrug adjustment; and the highest estimate derived from the higher treatment rates.

###### 

Predicted/modeled demand estimate and sensitivity analyses taking into account polydrug use
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  Drug type                                             Demand -- main estimate   Demand -- polydrug adjustment   SA 1: Minimum severity distribution polydrug   SA 2: Maximum severity polydrug   SA 3: Minimum treatment rate polydrug   SA 4: Maximum treatment rate polydrug
  ----------------------------------------------------- ------------------------- ------------------------------- ---------------------------------------------- --------------------------------- --------------------------------------- ---------------------------------------
  Alcohol                                               348,094                   348,094                         318,594                                        397,260                           294,012                                 435,609
  Cannabis                                              93,716                    27,646                          23,741                                         31,551                            20,695                                  42,484
  Other drugs (amphetamine, benzodiazepine & opioids)   152,141                   127,600                         95,793                                         127,483                           97,033                                  143,262
  Total treated                                         593,951                   503,340                         438,128                                        556,294                           411,740                                 621,355

*Note:* SA = sensitivity analysis.

Comparison of the findings with estimates of current met demand
---------------------------------------------------------------

[@B8] estimated that between 202,168 and 232,419 individuals received treatment in Australia in 2011/2012. This is the only comprehensive estimate of the met demand for Australia. Applying those figures to the total demand estimated here reveals that the proportion of demand currently being met ranges between 26.8% and 56.4% ([Table 6](#T6){ref-type="table"}). If this is translated into numbers of people, the additional number of people to be treated in any one year in Australia to meet predicted demand may be as high as 553,389 more people (that is if total demand = 755,557 less current met demand of 202,168) or as low as 179,321 more people (where total demand = 411,740 less met demand of 232,419).

###### 

Extent of potential met demand
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  Variable                                      Plausible numbers to be treated   \% met demand -- based on low estimate of current met demand (202,168) [@B8]   \% met demand, based on high estimate of current met demand (232,419), [@B8]
  --------------------------------------------- --------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------
  DASP model main estimate                      593,951                           34.0%                                                                          39.1%
  DASP modelaccounting for polydrug disorders   503,340                           40.2%                                                                          46.2%
  Sensitivity Analysis 1                        518,761                           39.0%                                                                          44.8%
  Sensitivity Analysis 2                        661,490                           30.6%                                                                          35.1%
  Sensitivity Analysis 3                        483,250                           41.8%                                                                          48.1%
  Sensitivity Analysis 4                        755,557                           26.8%                                                                          30.8%
  Sensitivity Analysis Polydrug 1               438,128                           46.1%                                                                          53.0%
  Sensitivity Analysis Polydrug 2               556,294                           36.3%                                                                          41.8%
  Sensitivity Analysis Polydrug 3               411,740                           49.1%                                                                          56.4%
  Sensitivity Analysis Polydrug 4               621,355                           32.5%                                                                          37.4%

*Note:* DASP = Drug and Alcohol Service Planning.

Discussion
==========

Planning for the appropriate amount of AOD treatment requires demand estimation. The work reported herein used a unique demand-based projection model to estimate the number of Australians who are appropriate for and would seek AOD treatment and then matched this against an estimate of met demand. Between 180,000 and 553,000 more people would be in treatment if demand were to be met; or stated differently, current met demand represents between 26.8% and 56.4% of the current Australian potential treatment population.

These modeled demand rates from the application of a unique and complex model should be higher than those reported for existing treatment utilization (effectively selfreported met demand). [@B1] reported a met demand rate between 8.1% (harmful) and 13.6% (dependence) for alcohol. More recent Australian estimates from the same survey source (the National Survey of Mental Health and Wellbeing) reported between 15.5% (harmful alcohol) and 52.4% (any drug dependence), with an average of 24% ([@B43]; [@B47], [@B48]). This suggests that the low modeled estimate (at 26.8%) is not unreasonable and accords with self-reported met demand.

Benchmarking the Australian results against estimates published from other developed countries suggests that, with the met demand falling between 27% and 56%, Australia has a relatively high rate of met demand. For other countries, estimates below or around 10% were reported for alcohol ([@B10]; [@B15], [@B14]; [@B18]), and a high estimate for alcohol use disorders was 22% ([@B26]). For substance use disorders, the estimates ranged between 12% and 33% ([@B6]; [@B29]; [@B33]; [@B40]; [@B44]; [@B46]). The figures reported herein are the first for Australia and contribute to this growing body of international literature regarding the size of the gap between met and unmet demand for AOD treatment.

As with any modeling work, there are many limitations, largely concerned with the series of assumptions that are required. The epidemiological prevalence data derived from 1997 and included both abuse and dependence diagnoses---arguably overestimating treatment need from the start. However, the inclusion of a mild severity category mitigated this. The average treatment rate across the model was 35% (excluding opioids), appearing quite modest. The sensitivity analyses address this, but it remains an open question for expert judgment. Gender was not included in the original DASP model---a limitation given the known differences in treatment seeking between males and females ([@B23]). The published analysis of met demand ([@B8]) did not distinguish between drug classes, yet the predicted unmet demand will vary by drug class and by age group. The lack of detailed analyses of current met demand limits the opportunities for further analysis of the predicted demand, and more specific areas of high need. More generally, a limitation with this and other such models is that they are predicated on the existence of an identifiable and somewhat mature treatment service system, in which there are readily identifiable specialist services, evidence-based treatments are provided, and planning units are dedicated to determining the number, type, and spread of treatment services. This is rarely the case in developing countries ([@B50]); hence, this population-based planning model is appropriate only for developed countries.

These analyses highlight that planning requires more than simply a quantitative model to predict demand. Consistent with all approaches to planning and needs assessment, multiple methods are required in order to gain a full picture of treatment gaps ([@B17]). The perceptions of practitioners, clients, and the community are as important as the mathematical quantifications. Nonetheless, it is quite clear that there is a significant gap between the provision of AOD treatment in Australia and the existing demand for treatment. This gap represents a significant cost to society---not just in economic terms (where the burden of untreated substance use disorders is substantial; [@B11]), but also in terms of the physical and psychological effects (pain and suffering) that could be alleviated with the provision of treatment.
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